12月25日,国家知识产权局官网发布一则公告,理论在2036年才到期的巴瑞替尼晶型专利ZL201610136379.8,提前10多年就被宣告全部无效。此次专利无效请求人南京力博维制药。巴瑞替尼是礼来的独家品种,原研厂家是Incyte,礼来拥有其全球开发及销售权益。2019年,该药在我国首次获批,直至今年4月16日,已经斩获了三项适应症,目前已知可用于治疗类风湿性关节炎、斑秃。因为这款药能够治疗脱发...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.